Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report-Reference-Cited by-同舟云学术

Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report

Published:2023-12-01 Issue:12 Volume:10 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Sunagawa Shawnalyn W¹,Havens Joshua P¹²,Podany Anthony¹^ORCID,Walker Bryan²,Scarsi Kimberly K¹²,Bares Sara H²

Affiliation:

1. College of Pharmacy, University of Nebraska Medical Center , Omaha, Nebraska , USA

2. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center , Omaha, Nebraska , USA

Abstract

Abstract As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug–drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofad604/53976216/ofad604.pdf

Reference12 articles.

1. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV;Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America

2. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculosis meningitis;Torok;Clin Infect Dis,2011

3. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects;Ford;Antimicrob Agents Chemother,2017

4. Cabenuva product label;US Food and Drug Administration

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability;Clinical Infectious Diseases;2024-07-11

2. Clinical pharmacology considerations and drug–drug interactions with long‐acting cabotegravir and rilpivirine relevant to sub‐Saharan Africa;British Journal of Clinical Pharmacology;2024-06-25

3. Development of a physiologically‐based pharmacokinetic model to simulate the pharmacokinetics of intramuscular antiretroviral drugs;CPT: Pharmacometrics & Systems Pharmacology;2024-03